Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

BACKGROUND: Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). However, the underlying molecular mechanism of apatinib on NSCLC remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chunfeng, Zhou, Xu, Liang, Chunhua, Li, Xiaoting, Ge, Miaomiao, Chen, Yue, Yin, Juan, Zhu, Jianyun, Zhong, Caiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385858/
https://www.ncbi.nlm.nih.gov/pubmed/34429133
http://dx.doi.org/10.1186/s13046-021-02069-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385858/
https://www.ncbi.nlm.nih.gov/pubmed/34429133
http://dx.doi.org/10.1186/s13046-021-02069-4

Ejemplares similares